

**B. In the Claims**

Please amend claims 71 and 76 as indicated. Pursuant to the present amendment, the status of the claims will be as follows:

1 to 46. (Cancelled)

47. (Previously presented) The method of claim 71, wherein amplified ORFs of the plurality encode full length proteins.

48 to 56. (Cancelled)

57. (Previously presented) The method of claim 71, wherein the DNA molecules comprise prokaryotic DNA or eukaryotic DNA.

58. (Cancelled)

59. (Previously presented) The method of claim 71, wherein the amplified ORFs of the plurality encode members of a family of proteins.

60. (Previously presented) The method of claim 59, wherein the members of the family of proteins are human proteins.

61. (Previously presented) The method of claim 59, wherein the members of the family of proteins comprises members of a family of kinases, phosphatases, transcription factors, oncogenes, or tumor suppressors.

DEC 16 2003

TECH CENTER 1000/2000

62. (Previously presented) The method of claim 71, which is performed in a high throughput format.

63. (Previously presented) The method of claim 71, which is performed in a multiwell microtiter plate.

64 to 70. (Cancelled)

71. (Currently amended) A method for producing a library of selected expressible open reading frames (ORFs), the method comprising:

a) amplifying deoxyribonucleic acid (DNA) molecules comprising a plurality of ORFs using a primer pair, wherein the primer pair comprises a 5' primer, which comprises a nucleotide ~~sequences~~ sequence starting 5'-CACCATG (SEQ ID NO:7), and a 3' primer, which causes the amplification product to end ~~just prior to~~ immediately preceding a stop codon, thereby producing a plurality of amplified ORFs;

b) purifying amplified ORFs of the plurality, thereby obtaining purified amplified ORFs;

c) inserting the purified amplified ORFs into expression vectors using an enzyme selected from the group consisting of a vaccinia DNA topoisomerase, a lambda integrase, an FLP recombinase, and a P1-Cre protein, thereby producing expression vectors comprising the amplified ORFs;

d) transforming cells with the expression vectors comprising the amplified ORFs; and

e) selecting transformed cells containing expression vectors comprising ORFs in an orientation for expression of a polypeptide encoded by the ORF, thereby producing a library of selected expressible.

72. (Previously presented) The method of claim 71, wherein purifying the amplified ORFs comprises separating the amplified ORFs using agarose gel electrophoresis, and isolating the amplified ORFs from the agarose gel.

73. (Previously presented) The method of claim 72, wherein the agarose is low melt agarose.

74 and 75. (Cancelled)

76. (Currently amended) The method of claim 71, wherein the expression vectors are suitable for ~~prokaryotic expression and eukaryotic expression~~ of the ORF in a prokaryote and a eukaryote.

77 to 80. (Cancelled)